Effective October 16, 2018, Fecal Calprotectin (CALPRO) testing will be performed within Cleveland Clinic’s Microbiology Section.
The quantitative detection of calprotectin is an in vitro diagnostic test to aid in the diagnosis of inflammatory bowel disease (IBD) in conjunction with other clinical and laboratory findings.
Fecal calprotectin is an indicator of neutrophils in the stool and is not specific for IBD. Elevations in fecal calprotectin may be caused by proton pump inhibitors, non-steroid-anti-inflammatory-drugs, and intestinal impairments other than IBD (e.g., diverticulitis, celiac disease, infections, cancer).
Preserved stool specimens cannot be accepted.
Specimen Information
Specimen Type:
Unpreserved stool
Collection Container:
Sterile Specimen Container
Reference Ranges
Normal:
<50 mg/kg
Borderline:
50-120 mg/kg
Abnormal:
>120 mg/kg
Reporting Range:
27.1 to 3000 mg/kg
Methodology
QUANTA Lite® Extended Range ELISA (FDA-approved)
Limitations
Calprotectin results generated by the FDA-approved QUANTA Lite Extended Range Assay cannot be directly compared to those determined by other methods.
Any additional information will be included in a future Technical Update. If you have any questions about these changes, please contact Client Services for assistance.